ArticleThe Psychiatric quarterly2018
Elevated Plasma S100B, Psychotic Symptoms, and Cognition in Schizophrenia.
Article in The Psychiatric quarterly, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05105542 (Muscarinic M1 Receptor Availability and Cognition in Schizophrenia), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Muscarinic M1 Receptor Availability and Cognition in Schizophrenia
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Role of Ginkgo biloba extract as an adjunctive treatment of elderly patients with depression and on the expression of serum S100B.Medicine · 2018Trial
- Blood‑brain barrier dysfunction in schizophrenia: Mechanisms and implications (Review).International journal of molecular medicine · 2025Review
- Genetic and circulating biomarkers of cognitive dysfunction and dementia in CKD.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Review
- The relationship between inflammatory markers, clinical characteristics, and cognitive performance in drug-naïve patients with schizophrenia.European archives of psychiatry and clinical neuroscience · 2024Article
- Peripheral S100B Protein Levels in Five Major Psychiatric Disorders: A Systematic Review.Brain sciences · 2023Review
- Review
- Schizophrenia and Alarmins.Medicina (Kaunas, Lithuania) · 2022Review
- Plasma Soluble P-selectin, Interleukin-6 and S100B Protein in Patients with Schizophrenia: a Pilot Study.The Psychiatric quarterly · 2022Article
- Acute paranoid schizophrenia relapsed inpatients present summer/ winter but not day/night changes in serum S100B concentrations.Actas espanolas de psiquiatria · 2021Article
- Blood-brain barrier pathology in patients with severe mental disorders: a systematic review and meta-analysis of biomarkers in case-control studies.Brain, behavior, & immunity - health · 2020Article
- Oxidative-Antioxidant Imbalance and Impaired Glucose Metabolism in Schizophrenia.Biomolecules · 2020Review
- Racial Differences in S100b Levels in Persons with Schizophrenia.The Psychiatric quarterly · 2020Article
- Peripheral Biomarkers for First-Episode Psychosis-Opportunities from the Neuroinflammatory Hypothesis of Schizophrenia.Psychiatry investigation · 2019Article
- Minocycline as adjunct therapy for a male patient with deficit schizophrenia.Neuropsychiatric disease and treatment · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
S100B is a calcium binding protein mainly produced by glial cells. Previous studies have shown elevated levels of S100B in patients with schizophrenia. We measured S100B levels in fasting plasma of 39 patients with schizophrenia and 19 adult healthy controls. We used linear regression to compare S100B between patients and controls. In patients only, we also investigated the relationship between S100B levels and psychotic symptoms (assessed by the Positive and Negative Syndrome Scale), and cognitive function (assessed by the NIH Toolbox Cognition Battery), respectively by calculating Pearson's correlation coefficients. Mean plasma S100B was significantly higher in the patient group than in the control group. There were no significant correlations between plasma S100B and psychotic symptoms or cognition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.